Nothing Special   »   [go: up one dir, main page]

WO2003057847A8 - METHODS AND MATERIALS FOR MODULATING ENaC-BETA - Google Patents

METHODS AND MATERIALS FOR MODULATING ENaC-BETA

Info

Publication number
WO2003057847A8
WO2003057847A8 PCT/US2002/041850 US0241850W WO03057847A8 WO 2003057847 A8 WO2003057847 A8 WO 2003057847A8 US 0241850 W US0241850 W US 0241850W WO 03057847 A8 WO03057847 A8 WO 03057847A8
Authority
WO
WIPO (PCT)
Prior art keywords
beta
methods
materials
enac
modulating
Prior art date
Application number
PCT/US2002/041850
Other languages
French (fr)
Other versions
WO2003057847A2 (en
WO2003057847A3 (en
Inventor
Samuel J Shuster
Ulf N G Arvidsson
Laura S Stone
Hong-Yan Zhang
Lucy Vulchanova Hart
Original Assignee
Algos Therapeutics Inc
Samuel J Shuster
Ulf N G Arvidsson
Laura S Stone
Hong-Yan Zhang
Lucy Vulchanova Hart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algos Therapeutics Inc, Samuel J Shuster, Ulf N G Arvidsson, Laura S Stone, Hong-Yan Zhang, Lucy Vulchanova Hart filed Critical Algos Therapeutics Inc
Priority to AU2002364612A priority Critical patent/AU2002364612A1/en
Priority to US10/500,499 priority patent/US20080027015A1/en
Priority to EP02799996A priority patent/EP1478655A4/en
Publication of WO2003057847A2 publication Critical patent/WO2003057847A2/en
Publication of WO2003057847A3 publication Critical patent/WO2003057847A3/en
Publication of WO2003057847A8 publication Critical patent/WO2003057847A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of ENaC-beta. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding ENaC-beta.
PCT/US2002/041850 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA WO2003057847A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002364612A AU2002364612A1 (en) 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA
US10/500,499 US20080027015A1 (en) 2002-12-31 2002-12-31 Methods and Materials for Modulating Enac-Beta
EP02799996A EP1478655A4 (en) 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34606901P 2001-12-31 2001-12-31
US60/346,069 2001-12-31

Publications (3)

Publication Number Publication Date
WO2003057847A2 WO2003057847A2 (en) 2003-07-17
WO2003057847A3 WO2003057847A3 (en) 2003-12-11
WO2003057847A8 true WO2003057847A8 (en) 2004-01-15

Family

ID=23357796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/041850 WO2003057847A2 (en) 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA

Country Status (3)

Country Link
EP (1) EP1478655A4 (en)
AU (1) AU2002364612A1 (en)
WO (1) WO2003057847A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782966B2 (en) 1999-06-08 2005-09-15 University Of Iowa Research Foundation, The Compounds and methods to enhance RAAV transduction
AR066984A1 (en) 2007-06-15 2009-09-23 Novartis Ag INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
CN107929306B (en) 2010-04-23 2022-11-15 箭头制药公司 Organic compositions for the treatment of beta-ENaC-related diseases
WO2013155406A1 (en) * 2012-04-12 2013-10-17 The Chinese University Of Hong Kong Contragestion and treating inflammation by modulating sodium channel activity in the epithelium
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11684679B2 (en) 2016-03-07 2023-06-27 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
KR20200024793A (en) 2017-07-06 2020-03-09 애로우헤드 파마슈티컬스 인코포레이티드 RNAi Agents and Methods of Inhibiting the Expression of Alpha-ENaC

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975798A1 (en) * 1997-03-11 2000-02-02 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
US20030077773A1 (en) * 2000-12-06 2003-04-24 Brandon Rhonda C. Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof

Also Published As

Publication number Publication date
EP1478655A4 (en) 2006-05-10
WO2003057847A2 (en) 2003-07-17
WO2003057847A3 (en) 2003-12-11
AU2002364612A8 (en) 2003-07-24
EP1478655A2 (en) 2004-11-24
AU2002364612A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2002092772A3 (en) Antisense modulation of ptp1b expression
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
WO2003014307A3 (en) Antisense modulation of apolipoprotein(a) expression
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2003057843A8 (en) Methods and materials for modulating trpc4
WO2003008545A3 (en) Antisense modulation of glioma-associated oncogene-2 expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2002062951A3 (en) Antisense modulation of casein kinase 2-alpha prime expression
WO2002062954A3 (en) Antisense modulation of casein kinase 2-beta expression
WO2003057847A8 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2003050244A3 (en) Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO2004050674A3 (en) Methods and materials for modulating trpm2
WO2003031576A3 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression
WO2003057898A3 (en) Methods and materials for modulating p2x2
WO2003057846A3 (en) Methods and materials for modulating task-3
WO2003040339A3 (en) Antisense modulation of purinoreceptor p2x¿3?
EP1448762A4 (en) Antisense modulation of toll-like receptor 4 expression field of the invention

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 29/2003 UNDER (71) REPLACE "PLYMOUTH,MI 55442 (US)." BY "PLYMOUTH, MN55442 (US)."; UNDER (72, 75) FOR APPLICANTS AND INVENTORS "SHUSTER, SAMUEL, J.", "STONE, LAURA, S." AND "HART, LUCY VULCHANOVA" REPLACE "MI" BY "MN"

WWE Wipo information: entry into national phase

Ref document number: 2002799996

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002799996

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10500499

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10500499

Country of ref document: US